1Geerts WH,Bergqvist D,Pineo GF,et al.Prevention of venous thromboembolism:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines(8th edition).Chest,2008;133(6 Suppl):381S-453S.
3Geerts WH,Pineo GF,Heit JA,et al.Prevention of venous thromboembolism:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest,2004;126(3 Suppl):338S-400S.
4Jaffer AK,Barsoum WK,Krebs V,et al.Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty.Mayo Clin Proc,2005;80(6):732-738.
5Zaw HM,Osborne IC,Pettit PN,et al.Risk factors for venous thromboembolism in orthopedic surgery.Isr Med Assoc J,2002;4(11):1040-1042.
6Rafee A,Herlikar D,Gilbert R,et al.D-Dimer in the diagnosis of deep vein thrombosis following total hip and knee replacement:a prospective study.Ann R Coll Surg Engl,2008;90(2):123-126.
8Kubitza D,Becka M,Wensing G,et al.Safety,pharmacodynamics,and pharmacokinetics of BAY 59-7939:an oral,direct Factor Ⅹ a inhibitor:after multiple dosing in healthy male subjects.Eur J Clin Pharmacol,2005;61(12):873-880.
9Garcia D,Libby E,Crowther MA.The new oral anticoagulants.Blood,2010;115(1):15-20.
10Weinz C,Buetehorn U,Daehler HP,et al.Pharmacokinetics of BAY 59-7939:an oral,direct factor Ⅹa inhibitor:in rats and dogs.Xenobiotica,2005;35(9):891-910.
4Planes A, Vochelle N, Fagola M. Total hip replacement and deep vein thrombosis: a venographic and necropsy study. J Bone Joint Surg (Br), 1990, 72: 9-13.
5Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg (Am), 1999, 81: 932-940.
6Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg (Am), 2001, 83: 900-906.
7Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg (Am), 2005, 87: 2097-2112.
8Fiessinger JN. Huisman MV, Davidson BL. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA, 2005, 293: 681-689.
9Choi BY, Huo MH. Venous thromboembolism following total knee replacement. J Surg Orthop Adv, 2007, 16: 31-35.
10Bickler P, Brandes J, Lee M, et al. Bleeding complications from femoral and sciatic nerve catheters in patients receiving low molecular weight heparin. Anesth Analg, 2006, 103: 1036-1037.
